Quick answer: latest quarter results, by ticker or company name

Reported Q: Q4 2024 Rev YoY: -80.1% EPS YoY: +38.5% Move: -4.92%

Palatin Technologies Inc

PTN

$16.03 -4.92%

Exchange AMEX Sector Healthcare Industry Biotechnology

Q4 2024

Published: Sep 30, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for PTN

Reported

Report Date

Sep 30, 2024

Quarter Q4 2024

Revenue

350.00K

YoY: -80.1%

EPS

-0.56

YoY: +38.5%

Market Move

-4.92%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $0.35M down 80.1% year-over-year
EPS of $-0.56 increased by 38.5% from previous year
Gross margin of 51.5%
Net income of -8.25M
"'we are ready to complete the PL9643 Phase III program with all remaining clinical studies to be conducted and completed in calendar year 2025 and an anticipated NDA filing in the first half of calendar year 2026.'" - Carl Spana

PTN

Company PTN

Period Q4 2024

Currency USD

Report Type Quarterly Earnings

Generated Feb 11, 2026

Executive Summary

- Palatin reported a Q4 fiscal 2024 quarter with meaningful top-line sparsity following the December 2023 sale of Vyleesi rights to Cosette Pharmaceuticals, resulting in no recorded product sales for the quarter. The quarter posted revenue of 0.35 million and a net loss of 8.25 million, translating to an EPS of -0.56. Operating expenses remained elevated at 8.69 million, contributing to an EBITDA of -8.13 million and an operating loss of -8.34 million. For the full fiscal year 2024, the company benefited from a $7.8 million gain on Vyleesi’s sale, which helped reduce overall annual operating expenses versus the prior year, but Palatin still ended FY2024 with a net loss of 29.7 million as cash burn persisted.

Key Performance Indicators

Revenue

Decreasing

350.00K

QoQ: N/A | YoY: -80.14%

Gross Profit

Decreasing

180.09K

51.45% margin

QoQ: 204.83% | YoY: -89.14%

Operating Income

Increasing

-8.34M

QoQ: 9.26% | YoY: 22.89%

Net Income

Increasing

-8.25M

QoQ: 2.20% | YoY: 23.00%

EPS

Increasing

-0.56

QoQ: -5.66% | YoY: 38.46%

Revenue Trend

Margin Analysis

Financial Highlights

- Revenue (Q4 2024): 0.35 million; Gross profit: 0.18 million; Gross margin: 51.45% for the quarter; Operating expenses: 8.69 million; EBITDA: -8.13 million; Operating income: -8.34 million; Net income: -8.25 million; EPS: -0.56; Cash and cash equivalents (as of 2024-06-30): 9.53 million; Net cash used in operating activities (Q4 2024): -6.47 million; Fiscal year 2024 total operating expenses: 27.0 million; Fiscal year 2024 net cash used in operating activities: -31.5 million; Fiscal year 2024 net loss: -29.7 million; 2024 Vyleesi annual gross product sales: 8.9 million; 2024 Vyleesi net product revenue: 4.5 million; NDA timeline: PL9643 Phase III MELODY-1 data supportive; Planned NDA filing for PL9643 in the first half of calendar year 2026; Interim data for PL8177 in UC, and ongoing ocular programs PL9588 and PL9654 progressing toward IND-enabling studies in 2025.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	350.00K	-80.14%	N/A
Gross Profit	180.09K	-89.14%	204.83%
Operating Income	-8.34M	22.89%	9.26%
Net Income	-8.25M	23.00%	2.20%
EPS	-0.56	38.46%	-5.66%

Key Financial Ratios

Gross Profit Margin

Good

51.50%

Gross profit margin is healthy and competitive within industry standards

Operating Profit Margin

Weak

-23.83%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-23.57%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.77%

Return on assets suggests inefficient capital allocation

Return on Equity

Strong

74.00%

Return on equity demonstrates excellent capital efficiency and value creation

Current Ratio

Adequate

1.01

Current ratio meets minimum requirements but limited cushion

Debt to Equity

Conservative

-5.29

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-0.83x

Negative earnings make P/E ratio not meaningful

Price to Book

Undervalued

-245.18x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q1 2026	0.00	4.26	+0.0%	View
Q3 2025	0.00	-0.18	+0.0%	View
Q2 2025	0.00	-0.12	+0.0%	View
Q1 2025	0.00	-0.39	+0.0%	View
Q4 2024	0.35	-0.56	-80.1%	View

PTN

Palatin Technologies Inc

Q1 2026 Report

Palatin Technologies Inc (PTN) QQ1 2026 Results: Boehringer Ingelheim Collaboration Drives Non-Dilutive Revenue; IND Readiness for PL-7737 and Expansi...

Read full report

PTN

Palatin Technologies Inc

Q3 2025 Report

Palatin Technologies Inc (PTN) QQ3 2025 Results — Obesity Pipeline Momentum Amid Liquidity Constraints and Delisting Risk...

Read full report

PTN

Palatin Technologies Inc

Q2 2025 Report

Palatin Technologies Inc (PTN) QQ2 2025 Results Analysis - Q2 FY2025: Strategic Pivot to MC4R Obesity/Cerebral Plexus, Modest Near-Term Financials, an...

Read full report

PTN

Palatin Technologies Inc

Q1 2025 Report

Palatin Technologies Inc (PTN) QQ1 2025 Results — Strategic pivot to Melanocortin-4 (MCR-4) obesity assets amid ocular/GI BD opportunities; Q1 2025 ...

Read full report

Palatin Technologies Inc (PTN) Q4 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More PTN Quarterly Reports

PTN

PTN

PTN

PTN

Q4 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

PTN Full Profile

PTN Financial Statements

Earnings Calendar